Multiple myeloma trials in United States

In United States 299 Also abroad 704

299 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Where
Columbus, Derby, Guilford, Jacksonville, Kansas City, New Haven, North Haven, Oklahoma City, Overland Park, Phoenix, Richmond, Rochester, Tampa, Torrington, Washington D.C., Westwood
Age
18 years and over
People
26
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06465316
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Ann Arbor, Boston, Charlotte, Dallas, Hillsborough, Los Angeles, New Haven, New York, Portland, Salt Lake City, Tacoma, Winston-Salem
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00
Phase 4Taking people
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Where
Baton Rouge, Bethesda, Los Angeles, Lubbock, Reno, St. Petersburg, Tacoma
Age
18 years and over
People
30
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07609940
No phaseTaking people
Tissue Collection for Studies of Lymph Cancer
Where
Bethesda
Age
18 years and over
People
1,295 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT01676805
Phase 1/2Taking people
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Where
Ann Arbor, Atlanta, Columbus, Detroit, Houston, Indianapolis, Louisville, Miami, New Brunswick, New York, Portland, Seattle, Tampa
Age
18 years and over
People
387 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03761108 · EU 2024-511454-45-00
Phase 1/2Taking people
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Where
Charlotte, Winston-Salem
Age
18 years and over
People
70
Run by
Wake Forest University Health Sciences
See details and how to joinNCT04822337
Phase 1/2Taking people
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Where
Atlanta, Birmingham, Boston, Chicago, Columbus, Duarte, Hackensack, Irvine, Madison, Miami, Milwaukee, New York, Salt Lake City, Seattle, St Louis
Age
18 years and over
People
246 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00
No phaseTaking people
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Where
Birmingham, Boston, Charlotte, Columbus, Dallas, Durham, Los Angeles, New York, Richmond, Salt Lake City, San Francisco, Weston
Age
40 years and over
People
400
Run by
Tufts Medical Center
See details and how to joinNCT06365060
Phase 1Taking people
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
Where
New York
Age
18 years and over
People
32
Run by
Weill Medical College of Cornell University
See details and how to joinNCT07725406
Phase 2Not yet taking people in United States
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
Where
Charlottesville
Age
18 years and over
People
26
Run by
University of Virginia
See details and how to joinNCT07895017
Phase 2Taking people
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Where
Chicago, Salt Lake City
Age
18 years and over
People
40
Run by
University of Utah
See details and how to joinNCT06517017
No phaseTaking people
Neurocognitive Trajectories After BCMA CAR-T
Where
Charlotte
Age
18 years and over
People
50
Run by
Wake Forest University Health Sciences
See details and how to joinNCT07740317
Phase 1Taking people
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Where
Ann Arbor, Atlanta, Boston, Charleston, Charlotte, Cleveland, Dallas, Durham, Hackensack, Houston, Jacksonville, Miami, Nashville, New York, Philadelphia, Rochester, San Francisco, Tacoma
Age
18 years and over
People
165 worldwide
Run by
K36 Therapeutics, Inc.
See details and how to joinNCT05651932 · EU 2022-500801-41-00
Phase 2Taking people
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
Where
Columbus, Duarte, Irvine, Winston-Salem
Age
60 years and over
People
164
Run by
City of Hope Medical Center
See details and how to joinNCT06052826
Phase 1Not yet taking people in United States
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
Where
Chicago
Age
18 years and over
People
32
Run by
University of Chicago
See details and how to joinNCT07871747
Phase 3Taking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Atlanta, Austin, Boston, Chapel Hill, Charlotte, Charlottesville, Chicago, Cleveland, Columbus, Dallas, Denver, Detroit, Durham, Gilbert, Goodyear, Great Neck, Houston, Jacksonville, Lexington, Los Angeles, Madison, Milwaukee, Newnan, New York, Orange, Philadelphia, Phoenix, Portland, Rochester, San Antonio, San Francisco, Seattle, Stanford, St Louis, Stony Brook, Tampa, The Bronx, Winston-Salem, Zion
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637
Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Atlanta, Denver, Detroit, Duarte, Irvine, St Louis
Age
18 years and over
People
186 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00
Phase 2Taking people
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Where
Houston
Age
18 years to 72 years
People
61
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT05776979
Phase 3Taking people
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
Where
Albert Lea, Bemidji, Brainerd, Deer River, Detroit Lakes, Duluth, Fosston, Hibbing, Mankato, Monticello, Rochester, Sandstone, Thief River Falls, Virginia, Worthington
Age
18 years and over
People
222
Run by
Mayo Clinic
See details and how to joinNCT06395441
Phase 1Taking people
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Where
Atlanta, Denver, Los Angeles, Milwaukee, Newport, New York, Rochester, San Antonio
Age
18 years and over
People
100
Run by
Nammi Therapeutics Inc
See details and how to joinNCT06582017
Phase 1Taking people
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Where
Chicago, Denver, Duarte, Grand Rapids, Irvine, Newnan, Tampa
Age
18 years and over
People
127 worldwide
Run by
AbbVie
See details and how to joinNCT07409246
Phase 1/2Taking people
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Where
Atlanta, Chapel Hill, Charlotte, Cincinnati, Columbus, Dallas, Denver, Duarte, Irvine, New York, Salt Lake City, San Francisco, Tampa, Winston-Salem
Age
18 years to 64 years
People
602 worldwide
Run by
AbbVie
See details and how to joinNCT06892522 · EU 2024-515770-27-00
Phase 2/3Taking people
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Where
Atlanta, Chapel Hill, Denver, Eugene, Fairfax, Fort Wayne, Los Angeles, Minneapolis, Nashville, New York, Roanoke, Rochester, Scottsdale, The Woodlands, Tyler
Age
18 years and over
People
680 worldwide
Run by
AbbVie
See details and how to joinNCT07095452 · EU 2025-520897-21-00
No phaseTaking people
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Where
Chicago, Miami, San Antonio
Age
18 years and over
People
400
Run by
University of Miami
See details and how to joinNCT05745285
Phase 1/2Taking people
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
Where
Duarte
Age
18 years and over
People
162
Run by
National Cancer Institute (NCI)
See details and how to joinNCT07463807